Overview

Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2007-11-08
Target enrollment:
Participant gender:
Summary
The purposes of this study are: - To determine the overall response rate of patients treated with at least 2 cycles of this regimen. - To determine the feasibility and toxicity of the combination of topotecan and docetaxel.
Phase:
Phase 2
Details
Lead Sponsor:
Aultman Health Foundation
Aultman Hospital
Collaborator:
GlaxoSmithKline
Treatments:
Docetaxel
Topotecan